HRP20230401T1 - Konstrukti protutijela za flt3 i cd3 - Google Patents
Konstrukti protutijela za flt3 i cd3 Download PDFInfo
- Publication number
- HRP20230401T1 HRP20230401T1 HRP20230401TT HRP20230401T HRP20230401T1 HR P20230401 T1 HRP20230401 T1 HR P20230401T1 HR P20230401T T HRP20230401T T HR P20230401TT HR P20230401 T HRP20230401 T HR P20230401T HR P20230401 T1 HRP20230401 T1 HR P20230401T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- polypeptide
- amino acid
- acid sequence
- group
- Prior art date
Links
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 67
- 229920001184 polypeptide Polymers 0.000 claims 55
- 102000004196 processed proteins & peptides Human genes 0.000 claims 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims 51
- 238000000034 method Methods 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 241000288950 Callithrix jacchus Species 0.000 claims 1
- 241000282553 Macaca Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000288960 Saguinus oedipus Species 0.000 claims 1
- 241000282696 Saimiri sciureus Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 102000049850 human FLT3 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Claims (20)
1. Konstrukt protutijela koji sadrži prvu veznu domenu koja se veže na ljudski FLT3 na površini ciljne stanice i drugu veznu domenu koja se veže na ljudski CD3 na površini T stanice, naznačen time što se prva vezna domena veže na epitop od FLT3 koji se nalazi unutar regije kao što je prikazano u SEQ ID NO: 819, pri čemu je navedeni konstrukt protutijela barem bispecifičan.
2. Konstrukt protutijela prema zahtjevu 1, naznačen time što se prva vezna domena veže se za ljudski i makaki FLT3.
3. Konstrukt protutijela prema zahtjevu 1 ili 2, naznačen time što je konstrukt protutijela u formatu odabranom iz skupine koja se sastoji od (scFv)2, scFv-mAb s jednom domenom, dijatijela i oligomera tih formata.
4. Konstrukt protutijela prema bilo kojem od prethodnih zahtjeva, naznačen time što prva vezna domena sadrži VH regiju koja sadrži CDR-H1, CDR-H2 i CDR-H3 i VL regiju koja sadrži CDR-L1, CDR-L2 i CDR-L3 koje su odabrane iz skupine koja sadrži:
SEQ ID NO: 151-156, SEQ ID NO: 161-166, SEQ ID NO: 171-176, SEQ ID NO: 181-186, SEQ ID NO: 191-196, SEQ ID NO: 201-206, SEQ ID NO: 211-216, SEQ ID NO: 221-226, SEQ ID NO: 231-236, SEQ ID NO: 241-246, SEQ ID NO: 251-256, SEQ ID NO: 261-266, SEQ ID NO: 271-276, SEQ ID NO: 281-286, SEQ ID NO: 291-296, SEQ ID NO: 301-306, SEQ ID NO: 311-316, SEQ ID NO: 321-326, SEQ ID NO: 331-336, SEQ ID NO: 341-346, SEQ ID NO: 351-356, SEQ ID NO: 361-366, SEQ ID NO: 371-376, SEQ ID NO: 381-386, SEQ ID NO: 391-396, SEQ ID NO: 401-406, SEQ ID NO: 411-416, SEQ ID NO: 421-426, SEQ ID NO: 431-436, SEQ ID NO: 441-446, SEQ ID NO: 451-456, SEQ ID NO: 461-466, SEQ ID NO: 471-476, SEQ ID NO: 481-486, SEQ ID NO: 491-496, SEQ ID NO: 501-506, SEQ ID NO: 511-516, SEQ ID NO: 521-526, SEQ ID NO: 531-536, SEQ ID NO: 541-546, SEQ ID NO: 551-556, SEQ ID NO: 561-566, SEQ ID NO: 571-576, SEQ ID NO: 581-586, SEQ ID NO: 591-596, SEQ ID NO: 601-606, SEQ ID NO: 611-616, SEQ ID NO: 621-626, SEQ ID NO: 631-636, SEQ ID NO: 641-646, SEQ ID NO: 651-656, SEQ ID NO: 661-666, SEQ ID SEQ ID NO: 691-696, SEQ ID NO: 701-706, SEQ ID NO: 711-716, SEQ ID NO: 721-726, SEQ ID NO: 731-736, SEQ ID NO: 741-746, i SEQ ID NO: 791-796.
5. Konstrukt protutijela prema zahtjevu 4, naznačen time što prva vezna domena sadrži VH regiju odabranu iz skupine koja se sastoji od onih prikazanih u SEQ ID NO: 157, SEQ ID NO: 167, SEQ ID NO: 177, SEQ ID NO: 187, SEQ ID NO: 197, SEQ ID NO: 207, SEQ ID NO: 217, SEQ ID NO: 227, SEQ ID NO: 237, SEQ ID NO: 247, SEQ ID NO: 257, SEQ ID NO: 267, SEQ ID NO: 277, SEQ ID NO: 287, SEQ ID NO: 297, SEQ ID NO: 307, SEQ ID NO: 317, SEQ ID NO: 327, SEQ ID NO: 337, SEQ ID NO: 347, SEQ ID NO: 357, SEQ ID NO: 367, SEQ ID NO: 377, SEQ ID NO: 387, SEQ ID NO: 397, SEQ ID NO: 407, SEQ ID NO: 417, SEQ ID NO: 427, SEQ ID NO: 437, SEQ ID NO: 447, SEQ ID NO: 457, SEQ ID NO: 467, SEQ ID NO: 477, SEQ ID NO: 487, SEQ ID NO: 497, SEQ ID NO: 507, SEQ ID NO: 517, SEQ ID NO: 527, SEQ ID NO: 537, SEQ ID NO: 547, SEQ ID NO: 557, SEQ ID NO: 567, SEQ ID NO: 577, SEQ ID NO: 587, SEQ ID NO: 597, SEQ ID NO: 607, SEQ ID NO: 617, SEQ ID NO: 627, SEQ ID NO: 637, SEQ ID NO: 647, SEQ ID NO: 657, SEQ ID NO: 667, SEQ ID NO: 697, SEQ ID NO: 707, SEQ ID NO: 717, SEQ ID NO: 727, SEQ ID NO: 737, SEQ ID NO: 747, i SEQ ID NO: 797.
6. Konstrukt protutijela prema zahtjevu 4 ili 5, naznačen time što prva vezna domena sadrži VL regiju odabranu iz skupine koja se sastoji od onih prikazanih u SEQ ID NO: 158, SEQ ID NO: 168, SEQ ID NO: 178, SEQ ID NO: 188, SEQ ID NO: 198, SEQ ID NO: 208, SEQ ID NO: 218, SEQ ID NO: 228, SEQ ID NO: 238, SEQ ID NO: 248, SEQ ID NO: 258, SEQ ID NO: 268, SEQ ID NO: 278, SEQ ID NO: 288, SEQ ID NO: 298, SEQ ID NO: 308, SEQ ID NO: 318, SEQ ID NO: 328, SEQ ID NO: 338, SEQ ID NO: 348, SEQ ID NO: 358, SEQ ID NO: 368, SEQ ID NO: 378, SEQ ID NO: 388, SEQ ID NO: 398, SEQ ID NO: 408, SEQ ID NO: 418, SEQ ID NO: 428, SEQ ID NO: 438, SEQ ID NO: 448, SEQ ID NO: 458, SEQ ID NO: 468, SEQ ID NO: 478, SEQ ID NO: 488, SEQ ID NO: 498, SEQ ID NO: 508, SEQ ID NO: 518, SEQ ID NO: 528, SEQ ID NO: 538, SEQ ID NO: 548, SEQ ID NO: 558, SEQ ID NO: 568, SEQ ID NO: 578, SEQ ID NO: 588, SEQ ID NO: 598, SEQ ID NO: 608, SEQ ID NO: 618, SEQ ID NO: 628, SEQ ID NO: 638, SEQ ID NO: 648, SEQ ID NO: 658, SEQ ID NO: 668, SEQ ID NO: 698, SEQ ID NO: 708, SEQ ID NO: 718, SEQ ID NO: 728, SEQ ID NO: 738, SEQ ID NO: 748, i SEQ ID NO: 798.
7. Konstrukt protutijela prema bilo kojem od zahtjeva 4 do 6, naznačen time što prva vezna domena sadrži VH regiju i VL regiju odabranu iz skupine koja se sastoji od parova VH regije i VL regije kao što je prikazano u SEQ ID NO: 157+158, SEQ ID NO: 167+168, SEQ ID NO: 177+178, SEQ ID NO: 187+188, SEQ ID NO: 197+198, SEQ ID NO: 207+208, SEQ ID NO: 217+218, SEQ ID NO: 227+228, SEQ ID NO: 237+238, SEQ ID NO: 247+248, SEQ ID NO: 257+258, SEQ ID NO: 267+268, SEQ ID NO: 277+278, SEQ ID NO: 287+288, SEQ ID NO: 297+298, SEQ ID NO: 307+308, SEQ ID NO: 317+318, SEQ ID NO: 327+328, SEQ ID NO: 337+338, SEQ ID NO: 347+348, SEQ ID NO: 357+358, SEQ ID NO: 367+368, SEQ ID NO: 377+378, SEQ ID NO: 387+388, SEQ ID NO: 397+398. , SEQ ID NO: 407+408, SEQ ID NO: 417+418, SEQ ID NO: 427+428, SEQ ID NO: 437+438, SEQ ID NO: 447+448, SEQ ID NO: 457+458, SEQ ID NO: 467+468, SEQ ID NO: 477+478, SEQ ID NO: 487+488, SEQ ID NO: 497+498, SEQ ID NO: 507+508, SEQ ID NO: 517+518, SEQ ID NO: 527+528, SEQ ID NO: 537+538, SEQ ID NO: 547+548, SEQ ID NO: 557+558, SEQ ID NO: 567+568, SEQ ID NO: 577+578, SEQ ID NO: 587+588, SEQ ID NO: 597+598, SEQ ID NO: 607+608, SEQ ID NO: 617+618, SEQ ID NO: 627+628, SEQ ID NO: 637+638, SEQ ID NO: 647+648, SEQ ID NO: 657+658, SEQ ID NO: 667+668, SEQ ID NO: 697+698, SEQ ID NO: 707+708, SEQ ID NO: 717+718, SEQ ID NO: 727+728, SEQ ID NO: 737+738, SEQ ID NO: 747+748, i SEQ ID NO: 797+798.
8. Konstrukt protutijela prema bilo kojem od zahtjeva 4 do 7, naznačen time što prva vezna domena sadrži polipeptid odabran iz skupine koja se sastoji od onih prikazanih u SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, SEQ ID NO: 209, SEQ ID NO: 219, i SEQ ID NO: 229, SEQ ID NO: 239, SEQ ID NO: 249, i SEQ ID NO: 259, SEQ ID NO: 269, SEQ ID NO: 279, i SEQ ID NO: 289, SEQ ID NO: 299, SEQ ID NO: 309, SEQ ID NO: 319, i SEQ ID NO: 329, SEQ ID NO: 339, SEQ ID NO: 349, i SEQ ID NO: 359, SEQ ID NO: 369, SEQ ID NO: 379, i SEQ ID NO: 389, SEQ ID NO: 399, SEQ ID NO: 409, SEQ ID NO: 419, i SEQ ID NO: 429, SEQ ID NO: 439, SEQ ID NO: 449, i SEQ ID NO: 459, SEQ ID NO: 469, SEQ ID NO: 479, i SEQ ID NO: 489, SEQ ID NO: 499, SEQ ID NO: 509, SEQ ID NO: 519, i SEQ ID NO: 529, SEQ ID NO: 539, SEQ ID NO: 549, i SEQ ID NO: 559, SEQ ID NO: 569, SEQ ID NO: 579, i SEQ ID NO: 589, SEQ ID NO: 599, SEQ ID NO: 609, SEQ ID NO: 619, i SEQ ID NO: 629, SEQ ID NO: 639, SEQ ID NO: 649, i SEQ ID NO: 659, SEQ ID NO: 669, SEQ ID NO: 699, SEQ ID NO: 709, SEQ ID NO: 719, i SEQ ID NO: 729, SEQ ID NO: 739, SEQ ID NO: 749, i SEQ ID NO: 799.
9. Konstrukt protutijela prema bilo kojem od zahtjeva 1 do 8, naznačen time što se druga vezna domena veže se za ljudski CD3 ipsilon i za Callithrix jacchus, Saguinus Oedipus ili Saimiri sciureus CD3 ipsilon.
10. Konstrukt protutijela prema bilo kojem od zahtjeva 1 do 9, koji sadrži:
(a) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, SEQ ID NO: 209, SEQ ID NO: 219, i SEQ ID NO: 229, SEQ ID NO: 239, SEQ ID NO: 249, i SEQ ID NO: 259, SEQ ID NO: 269, SEQ ID NO: 279, i SEQ ID NO: 289, SEQ ID NO: 299, SEQ ID NO: 309, SEQ ID NO: 319, i SEQ ID NO: 329, SEQ ID NO: 339, SEQ ID NO: 349, i SEQ ID NO: 359, SEQ ID NO: 369, SEQ ID NO: 379, i SEQ ID NO: 389, SEQ ID NO: 399, SEQ ID NO: 409, SEQ ID NO: 419, i SEQ ID NO: 429, SEQ ID NO: 439, SEQ ID NO: 449, i SEQ ID NO: 459, SEQ ID NO: 469, SEQ ID NO: 479, i SEQ ID NO: 489, SEQ ID NO: 499, SEQ ID NO: 509, SEQ ID NO: 519, i SEQ ID NO: 529, SEQ ID NO: 539, SEQ ID NO: 549, i SEQ ID NO: 559, SEQ ID NO: 569, SEQ ID NO: 579, i SEQ ID NO: 589, SEQ ID NO: 599, SEQ ID NO: 609, SEQ ID NO: 619, i SEQ ID NO: 629, SEQ ID NO: 639, SEQ ID NO: 649, i SEQ ID NO: 659, SEQ ID NO: 669, SEQ ID NO: 699, SEQ ID NO: 709, SEQ ID NO: 719, i SEQ ID NO: 729, SEQ ID NO: 739, SEQ ID NO: 749, i SEQ ID NO: 799;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 1-9; i
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, i SEQ ID NO: 103; i
• izborno His-tag, kao što je onaj prikazan u SEQ ID NO 10;
(b) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, SEQ ID NO: 209, SEQ ID NO: 219, i SEQ ID NO: 229, SEQ ID NO: 239, SEQ ID NO: 249, i SEQ ID NO: 259, SEQ ID NO: 269, SEQ ID NO: 279, i SEQ ID NO: 289, SEQ ID NO: 299, SEQ ID NO: 309, SEQ ID NO: 319, i SEQ ID NO: 329, SEQ ID NO: 339, SEQ ID NO: 349, i SEQ ID NO: 359, SEQ ID NO: 369, SEQ ID NO: 379, i SEQ ID NO: 389, SEQ ID NO: 399, SEQ ID NO: 409, SEQ ID NO: 419, i SEQ ID NO: 429, SEQ ID NO: 439, SEQ ID NO: 449, i SEQ ID NO: 459, SEQ ID NO: 469, SEQ ID NO: 479, i SEQ ID NO: 489, SEQ ID NO: 499, SEQ ID NO: 509, SEQ ID NO: 519, i SEQ ID NO: 529, SEQ ID NO: 539, SEQ ID NO: 549, i SEQ ID NO: 559, SEQ ID NO: 569, SEQ ID NO: 579, i SEQ ID NO: 589, SEQ ID NO: 599, SEQ ID NO: 609, SEQ ID NO: 619, i SEQ ID NO: 629, SEQ ID NO: 639, SEQ ID NO: 649, i SEQ ID NO: 659, SEQ ID NO: 669, SEQ ID NO: 699, SEQ ID NO: 709, SEQ ID NO: 719, i SEQ ID NO: 729, SEQ ID NO: 739, SEQ ID NO: 749, i SEQ ID NO: 799;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 1-9;
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, i SEQ ID NO: 103
• izborno peptidnu poveznicu koja ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 1-9;
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 104-134; i
• izborno His-tag, kao što je onaj prikazan u SEQ ID NO 10;
(c) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu QRFVTGHFGGLX1PANG (SEQ ID NO: 135) pri čemu X1 je Y ili H; i
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, SEQ ID NO: 209, SEQ ID NO: 219, i SEQ ID NO: 229, SEQ ID NO: 239, SEQ ID NO: 249, i SEQ ID NO: 259, SEQ ID NO: 269, SEQ ID NO: 279, i SEQ ID NO: 289, SEQ ID NO: 299, SEQ ID NO: 309, SEQ ID NO: 319, i SEQ ID NO: 329, SEQ ID NO: 339, SEQ ID NO: 349, i SEQ ID NO: 359, SEQ ID NO: 369, SEQ ID NO: 379, i SEQ ID NO: 389, SEQ ID NO: 399, SEQ ID NO: 409, SEQ ID NO: 419, i SEQ ID NO: 429, SEQ ID NO: 439, SEQ ID NO: 449, i SEQ ID NO: 459, SEQ ID NO: 469, SEQ ID NO: 479, i SEQ ID NO: 489, SEQ ID NO: 499, SEQ ID NO: 509, SEQ ID NO: 519, i SEQ ID NO: 529, SEQ ID NO: 539, SEQ ID NO: 549, i SEQ ID NO: 559, SEQ ID NO: 569, SEQ ID NO: 579, i SEQ ID NO: 589, SEQ ID NO: 599, SEQ ID NO: 609, SEQ ID NO: 619, i SEQ ID NO: 629, SEQ ID NO: 639, SEQ ID NO: 649, i SEQ ID NO: 659, SEQ ID NO: 669, SEQ ID NO: 699, SEQ ID NO: 709, SEQ ID NO: 719, i SEQ ID NO: 729, SEQ ID NO: 739, SEQ ID NO: 749, i SEQ ID NO: 799;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 1-9;
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, i SEQ ID NO: 103;
• polipeptid koji ima aminokiselinsku sekvencu QRFVTGHFGGLHPANG (SEQ ID NO: 137) ili QRFCTGHFGGLHPCNG (SEQ ID NO: 139); i
• izborno His-tag, kao što je onaj prikazan u SEQ ID NO 10;
(d) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 17, SEQ ID NO: 26, SEQ ID NO: 35, SEQ ID NO: 44, SEQ ID NO: 53, SEQ ID NO: 62, SEQ ID NO: 71, SEQ ID NO: 80, SEQ ID NO: 89, SEQ ID NO: 98, i SEQ ID NO: 101;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 8;
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 158, SEQ ID NO: 168, SEQ ID NO: 178, SEQ ID NO: 188, SEQ ID NO: 198, SEQ ID NO: 208, SEQ ID NO: 218, SEQ ID NO: 228, SEQ ID NO: 238, SEQ ID NO: 248, SEQ ID NO: 258, SEQ ID NO: 268, SEQ ID NO: 278, SEQ ID NO: 288, SEQ ID NO: 298, SEQ ID NO: 308, SEQ ID NO: 318, SEQ ID NO: 328, SEQ ID NO: 338, SEQ ID NO: 348, SEQ ID NO: 358, SEQ ID NO: 368, SEQ ID NO: 378, SEQ ID NO: 388, SEQ ID NO: 398, SEQ ID NO: 408, SEQ ID NO: 418, SEQ ID NO: 428, SEQ ID NO: 438, SEQ ID NO: 448, SEQ ID NO: 458, SEQ ID NO: 468, SEQ ID NO: 478, SEQ ID NO: 488, SEQ ID NO: 498, SEQ ID NO: 508, SEQ ID NO: 518, SEQ ID NO: 528, SEQ ID NO: 538, SEQ ID NO: 548, SEQ ID NO: 558, SEQ ID NO: 568, SEQ ID NO: 578, SEQ ID NO: 588, SEQ ID NO: 598, SEQ ID NO: 608, SEQ ID NO: 618, SEQ ID NO: 628, SEQ ID NO: 638, SEQ ID NO: 648, SEQ ID NO: 658, SEQ ID NO: 668, SEQ ID NO: 698, SEQ ID NO: 708, SEQ ID NO: 718, SEQ ID NO: 728, SEQ ID NO: 738, SEQ ID NO: 748, i SEQ ID NO: 798 i serinski ostatak na C-terminalnom kraju;
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 140; i
polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 157, SEQ ID NO: 167, SEQ ID NO: 177, SEQ ID NO: 187, SEQ ID NO: 197, SEQ ID NO: 207, SEQ ID NO: 217, SEQ ID NO: 227, SEQ ID NO: 237, SEQ ID NO: 247, SEQ ID NO: 257, SEQ ID NO: 267, SEQ ID NO: 277, SEQ ID NO: 287, SEQ ID NO: 297, SEQ ID NO: 307, SEQ ID NO: 317, SEQ ID NO: 327, SEQ ID NO: 337, SEQ ID NO: 347, SEQ ID NO: 357, SEQ ID NO: 367, SEQ ID NO: 377, SEQ ID NO: 387, SEQ ID NO: 397, SEQ ID NO: 407, SEQ ID NO: 417, SEQ ID NO: 427, SEQ ID NO: 437, SEQ ID NO: 447, SEQ ID NO: 457, SEQ ID NO: 467, SEQ ID NO: 477, SEQ ID NO: 487, SEQ ID NO: 497, SEQ ID NO: 507, SEQ ID NO: 517, SEQ ID NO: 527, SEQ ID NO: 537, SEQ ID NO: 547, SEQ ID NO: 557, SEQ ID NO: 567, SEQ ID NO: 577, SEQ ID NO: 587, SEQ ID NO: 597, SEQ ID NO: 607, SEQ ID NO: 617, SEQ ID NO: 627, SEQ ID NO: 637, SEQ ID NO: 647, SEQ ID NO: 657, SEQ ID NO: 667, SEQ ID NO: 697, SEQ ID NO: 707, SEQ ID NO: 717, SEQ ID NO: 727, SEQ ID NO: 737, SEQ ID NO: 747, i SEQ ID NO: 797;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 8;
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 18, SEQ ID NO: 27, SEQ ID NO: 36, SEQ ID NO: 45, SEQ ID NO: 54, SEQ ID NO: 63, SEQ ID NO: 72, SEQ ID NO: 81, SEQ ID NO: 90, SEQ ID NO: 99, i SEQ ID NO: 102 i serinski ostatak na C-terminalnom kraju;
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 141;
(e) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 17, SEQ ID NO: 26, SEQ ID NO: 35, SEQ ID NO: 44, SEQ ID NO: 53, SEQ ID NO: 62, SEQ ID NO: 71, SEQ ID NO: 80, SEQ ID NO: 89, SEQ ID NO: 98, i SEQ ID NO: 101;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 8;
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 158, SEQ ID NO: 168, SEQ ID NO: 178, SEQ ID NO: 188, SEQ ID NO: 198, SEQ ID NO: 208, SEQ ID NO: 218, SEQ ID NO: 228, SEQ ID NO: 238, SEQ ID NO: 248, SEQ ID NO: 258, SEQ ID NO: 268, SEQ ID NO: 278, SEQ ID NO: 288, SEQ ID NO: 298, SEQ ID NO: 308, SEQ ID NO: 318, SEQ ID NO: 328, SEQ ID NO: 338, SEQ ID NO: 348, SEQ ID NO: 358, SEQ ID NO: 368, SEQ ID NO: 378, SEQ ID NO: 388, SEQ ID NO: 398, SEQ ID NO: 408, SEQ ID NO: 418, SEQ ID NO: 428, SEQ ID NO: 438, SEQ ID NO: 448, SEQ ID NO: 458, SEQ ID NO: 468, SEQ ID NO: 478, SEQ ID NO: 488, SEQ ID NO: 498, SEQ ID NO: 508, SEQ ID NO: 518, SEQ ID NO: 528, SEQ ID NO: 538, SEQ ID NO: 548, SEQ ID NO: 558, SEQ ID NO: 568, SEQ ID NO: 578, SEQ ID NO: 588, SEQ ID NO: 598, SEQ ID NO: 608, SEQ ID NO: 618, SEQ ID NO: 628, SEQ ID NO: 638, SEQ ID NO: 648, SEQ ID NO: 658, SEQ ID NO: 668, SEQ ID NO: 698, SEQ ID NO: 708, SEQ ID NO: 718, SEQ ID NO: 728, SEQ ID NO: 738, SEQ ID NO: 748, i SEQ ID NO: 798;
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 142; i
polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 157, SEQ ID NO: 167, SEQ ID NO: 177, SEQ ID NO: 187, SEQ ID NO: 197, SEQ ID NO: 207, SEQ ID NO: 217, SEQ ID NO: 227, SEQ ID NO: 237, SEQ ID NO: 247, SEQ ID NO: 257, SEQ ID NO: 267, SEQ ID NO: 277, SEQ ID NO: 287, SEQ ID NO: 297, SEQ ID NO: 307, SEQ ID NO: 317, SEQ ID NO: 327, SEQ ID NO: 337, SEQ ID NO: 347, SEQ ID NO: 357, SEQ ID NO: 367, SEQ ID NO: 377, SEQ ID NO: 387, SEQ ID NO: 397, SEQ ID NO: 407, SEQ ID NO: 417, SEQ ID NO: 427, SEQ ID NO: 437, SEQ ID NO: 447, SEQ ID NO: 457, SEQ ID NO: 467, SEQ ID NO: 477, SEQ ID NO: 487, SEQ ID NO: 497, SEQ ID NO: 507, SEQ ID NO: 517, SEQ ID NO: 527, SEQ ID NO: 537, SEQ ID NO: 547, SEQ ID NO: 557, SEQ ID NO: 567, SEQ ID NO: 577, SEQ ID NO: 587, SEQ ID NO: 597, SEQ ID NO: 607, SEQ ID NO: 617, SEQ ID NO: 627, SEQ ID NO: 637, SEQ ID NO: 647, SEQ ID NO: 657, SEQ ID NO: 667, SEQ ID NO: 697, SEQ ID NO: 707, SEQ ID NO: 717, SEQ ID NO: 727, SEQ ID NO: 737, SEQ ID NO: 747, i SEQ ID NO: 797;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 8;
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 18, SEQ ID NO: 27, SEQ ID NO: 36, SEQ ID NO: 45, SEQ ID NO: 54, SEQ ID NO: 63, SEQ ID NO: 72, SEQ ID NO: 81, SEQ ID NO: 90, SEQ ID NO: 99, i SEQ ID NO: 102 i serinski ostatak na C-terminalnom kraju;
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 143;
(f) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, SEQ ID NO: 209, SEQ ID NO: 219, i SEQ ID NO: 229, SEQ ID NO: 239, SEQ ID NO: 249, i SEQ ID NO: 259, SEQ ID NO: 269, SEQ ID NO: 279, i SEQ ID NO: 289, SEQ ID NO: 299, SEQ ID NO: 309, SEQ ID NO: 319, i SEQ ID NO: 329, SEQ ID NO: 339, SEQ ID NO: 349, i SEQ ID NO: 359, SEQ ID NO: 369, SEQ ID NO: 379, i SEQ ID NO: 389, SEQ ID NO: 399, SEQ ID NO: 409, SEQ ID NO: 419, i SEQ ID NO: 429, SEQ ID NO: 439, SEQ ID NO: 449, i SEQ ID NO: 459, SEQ ID NO: 469, SEQ ID NO: 479, i SEQ ID NO: 489, SEQ ID NO: 499, SEQ ID NO: 509, SEQ ID NO: 519, i SEQ ID NO: 529, SEQ ID NO: 539, SEQ ID NO: 549, i SEQ ID NO: 559, SEQ ID NO: 569, SEQ ID NO: 579, i SEQ ID NO: 589, SEQ ID NO: 599, SEQ ID NO: 609, SEQ ID NO: 619, i SEQ ID NO: 629, SEQ ID NO: 639, SEQ ID NO: 649, i SEQ ID NO: 659, SEQ ID NO: 669, SEQ ID NO: 699, SEQ ID NO: 709, SEQ ID NO: 719, i SEQ ID NO: 729, SEQ ID NO: 739, SEQ ID NO: 749, i SEQ ID NO: 799;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 1-9; i
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, i SEQ ID NO: 103; i
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 144; i
polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 145;
(g) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, SEQ ID NO: 209, SEQ ID NO: 219, i SEQ ID NO: 229, SEQ ID NO: 239, SEQ ID NO: 249, i SEQ ID NO: 259, SEQ ID NO: 269, SEQ ID NO: 279, i SEQ ID NO: 289, SEQ ID NO: 299, SEQ ID NO: 309, SEQ ID NO: 319, i SEQ ID NO: 329, SEQ ID NO: 339, SEQ ID NO: 349, i SEQ ID NO: 359, SEQ ID NO: 369, SEQ ID NO: 379, i SEQ ID NO: 389, SEQ ID NO: 399, SEQ ID NO: 409, SEQ ID NO: 419, i SEQ ID NO: 429, SEQ ID NO: 439, SEQ ID NO: 449, i SEQ ID NO: 459, SEQ ID NO: 469, SEQ ID NO: 479, i SEQ ID NO: 489, SEQ ID NO: 499, SEQ ID NO: 509, SEQ ID NO: 519, i SEQ ID NO: 529, SEQ ID NO: 539, SEQ ID NO: 549, i SEQ ID NO: 559, SEQ ID NO: 569, SEQ ID NO: 579, i SEQ ID NO: 589, SEQ ID NO: 599, SEQ ID NO: 609, SEQ ID NO: 619, i SEQ ID NO: 629, SEQ ID NO: 639, SEQ ID NO: 649, i SEQ ID NO: 659, SEQ ID NO: 669, SEQ ID NO: 699, SEQ ID NO: 709, SEQ ID NO: 719, i SEQ ID NO: 729, SEQ ID NO: 739, SEQ ID NO: 749, i SEQ ID NO: 799; i
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 146; i
polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, i SEQ ID NO: 103; i
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 147;
(h) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, SEQ ID NO: 209, SEQ ID NO: 219, i SEQ ID NO: 229, SEQ ID NO: 239, SEQ ID NO: 249, i SEQ ID NO: 259, SEQ ID NO: 269, SEQ ID NO: 279, i SEQ ID NO: 289, SEQ ID NO: 299, SEQ ID NO: 309, SEQ ID NO: 319, i SEQ ID NO: 329, SEQ ID NO: 339, SEQ ID NO: 349, i SEQ ID NO: 359, SEQ ID NO: 369, SEQ ID NO: 379, i SEQ ID NO: 389, SEQ ID NO: 399, SEQ ID NO: 409, SEQ ID NO: 419, i SEQ ID NO: 429, SEQ ID NO: 439, SEQ ID NO: 449, i SEQ ID NO: 459, SEQ ID NO: 469, SEQ ID NO: 479, i SEQ ID NO: 489, SEQ ID NO: 499, SEQ ID NO: 509, SEQ ID NO: 519, i SEQ ID NO: 529, SEQ ID NO: 539, SEQ ID NO: 549, i SEQ ID NO: 559, SEQ ID NO: 569, SEQ ID NO: 579, i SEQ ID NO: 589, SEQ ID NO: 599, SEQ ID NO: 609, SEQ ID NO: 619, i SEQ ID NO: 629, SEQ ID NO: 639, SEQ ID NO: 649, i SEQ ID NO: 659, SEQ ID NO: 669, SEQ ID NO: 699, SEQ ID NO: 709, SEQ ID NO: 719, i SEQ ID NO: 729, SEQ ID NO: 739, SEQ ID NO: 749, i SEQ ID NO: 799; i
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 148; i
polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, i SEQ ID NO: 103; i
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 149;
(i) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, SEQ ID NO: 209, SEQ ID NO: 219, i SEQ ID NO: 229, SEQ ID NO: 239, SEQ ID NO: 249, i SEQ ID NO: 259, SEQ ID NO: 269, SEQ ID NO: 279, i SEQ ID NO: 289, SEQ ID NO: 299, SEQ ID NO: 309, SEQ ID NO: 319, i SEQ ID NO: 329, SEQ ID NO: 339, SEQ ID NO: 349, i SEQ ID NO: 359, SEQ ID NO: 369, SEQ ID NO: 379, i SEQ ID NO: 389, SEQ ID NO: 399, SEQ ID NO: 409, SEQ ID NO: 419, i SEQ ID NO: 429, SEQ ID NO: 439, SEQ ID NO: 449, i SEQ ID NO: 459, SEQ ID NO: 469, SEQ ID NO: 479, i SEQ ID NO: 489, SEQ ID NO: 499, SEQ ID NO: 509, SEQ ID NO: 519, i SEQ ID NO: 529, SEQ ID NO: 539, SEQ ID NO: 549, i SEQ ID NO: 559, SEQ ID NO: 569, SEQ ID NO: 579, i SEQ ID NO: 589, SEQ ID NO: 599, SEQ ID NO: 609, SEQ ID NO: 619, i SEQ ID NO: 629, SEQ ID NO: 639, SEQ ID NO: 649, i SEQ ID NO: 659, SEQ ID NO: 669, SEQ ID NO: 699, SEQ ID NO: 709, SEQ ID NO: 719, i SEQ ID NO: 729, SEQ ID NO: 739, SEQ ID NO: 749, i SEQ ID NO: 799;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 1-9; i
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, i SEQ ID NO: 103; i
• polipeptid koji ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 150; ili
(j) polipeptid koji sadrži u sljedećem redoslijedu počevši od N-terminalnog kraja:
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 159, SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, SEQ ID NO: 209, SEQ ID NO: 219, i SEQ ID NO: 229, SEQ ID NO: 239, SEQ ID NO: 249, i SEQ ID NO: 259, SEQ ID NO: 269, SEQ ID NO: 279, i SEQ ID NO: 289, SEQ ID NO: 299, SEQ ID NO: 309, SEQ ID NO: 319, i SEQ ID NO: 329, SEQ ID NO: 339, SEQ ID NO: 349, i SEQ ID NO: 359, SEQ ID NO: 369, SEQ ID NO: 379, i SEQ ID NO: 389, SEQ ID NO: 399, SEQ ID NO: 409, SEQ ID NO: 419, i SEQ ID NO: 429, SEQ ID NO: 439, SEQ ID NO: 449, i SEQ ID NO: 459, SEQ ID NO: 469, SEQ ID NO: 479, i SEQ ID NO: 489, SEQ ID NO: 499, SEQ ID NO: 509, SEQ ID NO: 519, i SEQ ID NO: 529, SEQ ID NO: 539, SEQ ID NO: 549, i SEQ ID NO: 559, SEQ ID NO: 569, SEQ ID NO: 579, i SEQ ID NO: 589, SEQ ID NO: 599, SEQ ID NO: 609, SEQ ID NO: 619, i SEQ ID NO: 629, SEQ ID NO: 639, SEQ ID NO: 649, i SEQ ID NO: 659, SEQ ID NO: 669, SEQ ID NO: 699, SEQ ID NO: 709, SEQ ID NO: 719, i SEQ ID NO: 729, SEQ ID NO: 739, SEQ ID NO: 749, i SEQ ID NO: 799;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 1-9; i
• polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, i SEQ ID NO: 103;
• peptidnu poveznicu koja ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 1-9; i
• treću domenu koja ima aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO: 843-850.
11. Konstrukt protutijela prema bilo kojem od zahtjeva 1 do 10, koji sadrži ili se sastoji od polipeptida kao što je prikazano u bilo kojoj od SEQ ID NO: 856 to 871.
12. Konstrukt protutijela prema zahtjevu 1, koji sadrži ili se sastoji od polipeptida kao što je prikazano u SEQ ID NO: 862.
13. Polinukleotid koji kodira konstrukt protutijela kako je definiran u bilo kojem od prethodnih zahtjeva.
14. Vektor naznačen time što sadrži polinukleotid kako je definiran u zahtjevu 13.
15. Stanica domaćina transformirana ili transficirana s polinukleotidom kako je definiran u zahtjevu 13 ili s vektorom kako je definiran u zahtjevu 14.
16. Postupak za proizvodnju konstrukta protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što navedeni postupak uključuje uzgoj stanice domaćina kako je definirano u zahtjevu 15, pod uvjetima koji omogućuju ekspresiju konstrukta protutijela kako je definirano u bilo kojem od patentnih zahtjeva 1 do 12 i obnavljanje proizvedenog konstrukta antitijela iz kulture.
17. Farmaceutski pripravak koji sadrži konstrukt protutijela prema bilo kojem od zahtjeva 1 do 12, ili proizveden postupkom prema zahtjevu 16.
18. Konstrukt protutijela prema bilo kojem od zahtjeva 1 do 12, ili proizveden postupkom prema zahtjevu 16, za upotrebu u prevenciji ili liječenju hematološke bolesti raka ili metastatske kancerogene bolesti.
19. Konstrukt protutijela za upotrebu prema zahtjevu 18, naznačen time što je hematološka kancerogena bolest AML ili metastatska kancerogena bolest koja proizlazi iz bilo čega od prethodno navedenog.
20. Komplet koji sadrži konstrukt protutijela prema bilo kojem od zahtjeva 1 do 12, konstrukt protutijela proizveden postupkom prema zahtjevu 16, polinukleotid kako je definiran u zahtjevu 13, vektor kako je definiran u zahtjevu 14, i/ili stanica domaćina kako je definirana u zahtjevu 15.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199944P | 2015-07-31 | 2015-07-31 | |
| US201662290861P | 2016-02-03 | 2016-02-03 | |
| EP16756952.4A EP3328891B1 (en) | 2015-07-31 | 2016-08-01 | Antibody constructs for flt3 and cd3 |
| PCT/EP2016/068319 WO2017021362A1 (en) | 2015-07-31 | 2016-08-01 | Antibody constructs for flt3 and cd3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230401T1 true HRP20230401T1 (hr) | 2023-07-07 |
Family
ID=56800254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230401TT HRP20230401T1 (hr) | 2015-07-31 | 2016-08-01 | Konstrukti protutijela za flt3 i cd3 |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US11447567B2 (hr) |
| EP (2) | EP4219562A3 (hr) |
| JP (2) | JP7011574B2 (hr) |
| KR (1) | KR20180030852A (hr) |
| CN (2) | CN115925964A (hr) |
| AU (1) | AU2016302580B2 (hr) |
| BR (1) | BR112018001042A2 (hr) |
| CA (1) | CA2991607A1 (hr) |
| CL (3) | CL2018000269A1 (hr) |
| CO (1) | CO2018000882A2 (hr) |
| CR (1) | CR20180067A (hr) |
| CY (1) | CY1126145T1 (hr) |
| DK (1) | DK3328891T5 (hr) |
| EA (1) | EA201890337A8 (hr) |
| ES (1) | ES2943147T3 (hr) |
| FI (1) | FI3328891T3 (hr) |
| HR (1) | HRP20230401T1 (hr) |
| HU (1) | HUE061579T2 (hr) |
| IL (2) | IL289894B2 (hr) |
| JO (1) | JO3792B1 (hr) |
| LT (1) | LT3328891T (hr) |
| MD (1) | MD3328891T2 (hr) |
| MX (1) | MX2018001159A (hr) |
| MY (1) | MY193235A (hr) |
| PE (1) | PE20181082A1 (hr) |
| PH (1) | PH12018500157A1 (hr) |
| PL (1) | PL3328891T3 (hr) |
| PT (1) | PT3328891T (hr) |
| RS (1) | RS64184B1 (hr) |
| SG (1) | SG10202000793XA (hr) |
| SI (1) | SI3328891T1 (hr) |
| SM (1) | SMT202300131T1 (hr) |
| TN (1) | TN2017000550A1 (hr) |
| TW (1) | TWI829617B (hr) |
| UA (1) | UA125717C2 (hr) |
| WO (1) | WO2017021362A1 (hr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2769948C2 (ru) * | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| WO2010037838A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| ES2743809T3 (es) | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| IL293719B2 (en) | 2015-05-21 | 2023-07-01 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| JP7054924B2 (ja) | 2015-09-23 | 2022-04-15 | サイトイミューン セラピューティクス， インコーポレイテッド | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| UY37105A (es) | 2016-02-03 | 2017-09-29 | Amgen Res (Munich) Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| UA126657C2 (uk) | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| SG11201808622SA (en) * | 2016-04-01 | 2018-10-30 | Amgen Inc | Chimeric receptors to flt3 and methods of use thereof |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | Single domain serum albumin binding protein |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| PE20241587A1 (es) | 2017-06-02 | 2024-08-01 | Pfizer | Receptores de antigenos quimericos que se dirigen a flt3 |
| AU2018275359C1 (en) * | 2017-06-02 | 2022-02-03 | Pfizer Inc. | Antibodies specific for FLT3 and their uses |
| WO2019023097A1 (en) * | 2017-07-26 | 2019-01-31 | Smet Pharmaceutical Inc | ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE |
| IL312607B1 (en) | 2017-08-03 | 2025-04-01 | Amgen Inc | Interleukin-21 Mutants and Treatment Methods |
| CN116003405A (zh) | 2017-09-08 | 2023-04-25 | 美国安进公司 | Kras g12c的抑制剂及其使用方法 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| GB201721338D0 (en) * | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| BR112020014121A2 (pt) | 2018-01-12 | 2020-12-01 | Amgen Inc. | anticorpos anti-pd-1 e métodos de tratamento |
| AU2019228377B2 (en) * | 2018-02-27 | 2023-02-23 | Pfizer Inc. | Antibody purification |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| IL281683B2 (en) | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| CN114007642A (zh) | 2019-04-30 | 2022-02-01 | 森迪生物科学公司 | 嵌合受体及其使用方法 |
| CA3142440A1 (en) * | 2019-06-07 | 2020-12-10 | Amgen Inc. | Bispecific binding constructs |
| IL295448A (en) * | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
| WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| AU2021255884A1 (en) * | 2020-04-14 | 2022-11-17 | Les Laboratoires Servier | Anti-FLT3 antibodies and compositions |
| US20230159644A1 (en) | 2020-04-17 | 2023-05-25 | City Of Hope | Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies |
| WO2021242961A1 (en) * | 2020-05-27 | 2021-12-02 | Vanderbilt University | Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor |
| JP2023542257A (ja) | 2020-09-16 | 2023-10-05 | アムジェン インコーポレイテッド | 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法 |
| EP4291233A4 (en) * | 2021-02-10 | 2025-05-21 | Wugen, Inc. | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES |
| JP2024532173A (ja) * | 2021-08-17 | 2024-09-05 | ヒーモジェニックス ファーマシューティカルズ エルエルシー | 二重特異性抗ｆｌｔ３／ｃｄ３抗体及び使用方法 |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
| WO2025003511A1 (en) * | 2023-06-30 | 2025-01-02 | Morphosys Ag | Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| WO2025080688A1 (en) * | 2023-10-12 | 2025-04-17 | Amgen Inc. | Compositions of bispecific antibody constructs to human dll3 and human cd3 |
Family Cites Families (250)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447A (en) | 1846-04-04 | Car- wheel | ||
| US233A (en) | 1837-06-14 | Improvement in plows | ||
| US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| DE3850753T2 (de) | 1987-12-09 | 1995-03-16 | Omron Tateisi Electronics Co | Induktives Datenübertragungssystem. |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU664976B2 (en) | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| CA2105984C (en) | 1991-03-11 | 2002-11-26 | Milton J. Cormier | Cloning and expression of renilla luciferase |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| NZ253943A (en) | 1992-06-18 | 1997-01-29 | Genpharm Int | Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| DK0672141T3 (da) | 1992-10-23 | 2003-06-10 | Immunex Corp | Fremgangsmåder til fremstilling af opløselige, oligomere proteiner |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| NZ314644A (en) | 1993-05-24 | 2000-11-24 | Immunex Corp | Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue |
| US7045128B2 (en) | 1993-05-24 | 2006-05-16 | Immunex Corporation | Antibodies against flt3-ligand |
| ATE400651T1 (de) | 1993-09-10 | 2008-07-15 | Univ Columbia | Verwendung von grünem fluoreszenzprotein |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質／（ポリ）ペプチドライブラリー |
| DK0843961T3 (da) | 1995-08-29 | 2007-05-21 | Kirin Brewery | Kimærisk mus og fremgangsmåde til at producere samme |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
| WO1998026277A2 (en) | 1996-12-12 | 1998-06-18 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP2002507410A (ja) | 1998-03-27 | 2002-03-12 | プロルーム・リミテッド | ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用 |
| AU761587B2 (en) | 1998-04-21 | 2003-06-05 | Amgen Research (Munich) Gmbh | CD19xCD3 specific polypeptides and uses thereof |
| DE69911793T2 (de) | 1998-07-28 | 2004-08-12 | Micromet Ag | Heterominikörper |
| US7254167B2 (en) | 1998-10-30 | 2007-08-07 | Broadcom Corporation | Constellation-multiplexed transmitter and receiver |
| ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US7230167B2 (en) | 2001-08-31 | 2007-06-12 | Syngenta Participations Ag | Modified Cry3A toxins and nucleic acid sequences coding therefor |
| ES2645563T3 (es) | 2001-11-30 | 2017-12-05 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
| US8486859B2 (en) | 2002-05-15 | 2013-07-16 | Bioenergy, Inc. | Use of ribose to enhance plant growth |
| US7904068B2 (en) | 2003-06-06 | 2011-03-08 | At&T Intellectual Property I, L.P. | System and method for providing integrated voice and data services utilizing wired cordless access with unlicensed spectrum and wired access with licensed spectrum |
| MXPA05014152A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| WO2005032491A2 (en) * | 2003-10-03 | 2005-04-14 | Board Of Regents, University Of Texas System | Methods and compositions for mycoplasma pneumoniae exotoxins |
| DK1673398T3 (da) | 2003-10-16 | 2011-04-18 | Micromet Ag | Multispecifikke, deimmuniserede CD3-bindere |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| EP2228698B1 (en) | 2005-03-14 | 2012-06-27 | Omron Corporation | Programmable controller system |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| US8234145B2 (en) | 2005-07-12 | 2012-07-31 | International Business Machines Corporation | Automatic computation of validation metrics for global logistics processes |
| BRPI0604215A (pt) | 2005-08-17 | 2007-04-10 | Biosigma Sa | método para projetar oligonucleotìdeos para técnicas de biologia molecular |
| EP3178850B1 (en) | 2005-10-11 | 2021-01-13 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| JP2007122396A (ja) | 2005-10-27 | 2007-05-17 | Hitachi Ltd | ディスクアレイ装置及びその障害対応検証方法 |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| US7919297B2 (en) | 2006-02-21 | 2011-04-05 | Cornell Research Foundation, Inc. | Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase |
| US7574748B2 (en) | 2006-03-07 | 2009-08-18 | Nike, Inc. | Glove with support system |
| US8430938B1 (en) | 2006-07-13 | 2013-04-30 | The United States Of America As Represented By The Secretary Of The Navy | Control algorithm for autothermal reformer |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| KR101146588B1 (ko) | 2006-08-11 | 2012-05-16 | 삼성전자주식회사 | Ｆｉｎ 구조체 및 이를 이용한 핀 트랜지스터의 제조방법 |
| CN100589507C (zh) | 2006-10-30 | 2010-02-10 | 华为技术有限公司 | 一种拨号提示系统及方法 |
| US7466008B2 (en) | 2007-03-13 | 2008-12-16 | Taiwan Semiconductor Manufacturing Company, Ltd. | BiCMOS performance enhancement by mechanical uniaxial strain and methods of manufacture |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| SG10201808730VA (en) * | 2007-04-03 | 2018-11-29 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
| KR101626988B1 (ko) * | 2007-04-03 | 2016-06-02 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 이중특이적인 결합제들 |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| AU2008254951A1 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto |
| US8209741B2 (en) | 2007-09-17 | 2012-06-26 | Microsoft Corporation | Human performance in human interactive proofs using partial credit |
| US8464584B2 (en) | 2007-10-19 | 2013-06-18 | Food Equipment Technologies Company, Inc. | Beverage dispenser with level measuring apparatus and display |
| JP5675363B2 (ja) | 2007-11-29 | 2015-02-25 | シェフラー テクノロジーズ アクチエンゲゼルシャフト ウント コンパニー コマンディートゲゼルシャフトＳｃｈａｅｆｆｌｅｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ ＡＧ ＆ Ｃｏ． ＫＧ | 特に駆動機械と被駆動部との間の出力伝達のための動力伝達装置 |
| US8376279B2 (en) | 2008-01-23 | 2013-02-19 | Aurora Flight Sciences Corporation | Inflatable folding wings for a very high altitude aircraft |
| CN102089325A (zh) | 2008-04-17 | 2011-06-08 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽 |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| WO2010037838A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| JP6126782B2 (ja) | 2008-10-01 | 2017-05-10 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体 |
| WO2010045261A1 (en) | 2008-10-13 | 2010-04-22 | Zymogenetics, Llc | Single chain fc type iii interferons and methods of using same |
| JP4956801B2 (ja) | 2009-03-04 | 2012-06-20 | 日産自動車株式会社 | 排気ガス浄化触媒及びその製造方法 |
| PL2406284T3 (pl) | 2009-03-10 | 2017-09-29 | Biogen Ma Inc. | Przeciwciała anty-bcma |
| US8463191B2 (en) | 2009-04-02 | 2013-06-11 | Qualcomm Incorporated | Beamforming options with partial channel knowledge |
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| BR112012009450A2 (pt) | 2009-10-30 | 2017-05-23 | Novozymes Biopharma Dk As | variantes de albumina |
| CA2785178C (en) | 2009-12-23 | 2019-09-03 | Synimmune Gmbh | Anti-flt3 antibodies and methods of using the same |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| CN103124788B (zh) | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | 双特异性融合蛋白 |
| CN103347893A (zh) | 2010-11-01 | 2013-10-09 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| RS55995B2 (sr) | 2010-11-10 | 2024-04-30 | Amgen Res Munich Gmbh | Prevencija neželjenih efekata uzrokovanih cd3-specifičnim vezujućim domenima |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| KR20220082104A (ko) | 2010-11-30 | 2022-06-16 | 추가이 세이야쿠 가부시키가이샤 | 세포상해 유도 치료제 |
| TWI589589B (zh) | 2010-12-20 | 2017-07-01 | 建南德克公司 | 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物 |
| WO2012088461A2 (en) | 2010-12-23 | 2012-06-28 | Biogen Idec Inc. | Linker peptides and polypeptides comprising same |
| JP5745645B2 (ja) | 2010-12-30 | 2015-07-08 | ジョンソン コントロールズ メタルズ アンド メカニズムス ゲーエムベーハー アンド カンパニー カーゲー | ２つのレール対を備える自動車シート用前後調節装置 |
| AU2012251583B2 (en) | 2011-05-05 | 2017-06-08 | Albumedix Ltd. | Albumin variants |
| ES2659764T3 (es) | 2011-08-23 | 2018-03-19 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de linfocitos T |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| CL2014001263A1 (es) | 2011-11-15 | 2014-10-10 | Boehringer Ingelheim Int | Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes. |
| CN104168922A (zh) | 2011-11-16 | 2014-11-26 | 安姆根有限公司 | 治疗表皮生长因子缺失突变体viii相关疾病的方法 |
| WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| SI2794658T1 (sl) * | 2011-12-19 | 2017-05-31 | Synimmune Gmbh | Bispecifična molekula protitelesa |
| RU2014138474A (ru) | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| WO2013128027A1 (en) | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
| EP2825556B1 (en) | 2012-03-16 | 2018-01-03 | Albumedix A/S | Albumin variants |
| US9676858B2 (en) | 2012-06-07 | 2017-06-13 | Duke University | Human bispecific EGFRvIII antibody and CD3 engaging molecules |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| KR20150036606A (ko) | 2012-07-13 | 2015-04-07 | 자임워크스 인코포레이티드 | 항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체 |
| AU2013306076B2 (en) | 2012-08-21 | 2018-01-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| KR20150082422A (ko) | 2012-11-08 | 2015-07-15 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 변이체 |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| WO2014100490A1 (en) | 2012-12-19 | 2014-06-26 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
| CA3211863A1 (en) * | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| JP6133444B2 (ja) | 2013-02-26 | 2017-05-24 | ロシュ グリクアート アーゲー | 二重特異性ｔ細胞活性化抗原結合分子 |
| EA201591652A1 (ru) | 2013-03-06 | 2016-02-29 | Мерримак Фармасьютикалз, Инк. | ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| DK2970449T3 (da) | 2013-03-15 | 2019-11-25 | Amgen Res Munich Gmbh | Enkeltkædede bindingsmolekyler, der omfatter n-terminal abp |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| EP3424952A1 (en) | 2013-03-15 | 2019-01-09 | Amgen, Inc | Heterodimeric bispecific antibodies |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
| PL3019532T3 (pl) | 2013-07-09 | 2019-10-31 | Univ Duke | Ludzkie bispecyficzne cząsteczki angażujące przeciwciało egfrviii |
| WO2015018527A1 (en) | 2013-08-07 | 2015-02-12 | Affimed Therapeutics Ag | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| US20160257748A1 (en) | 2013-09-25 | 2016-09-08 | Amgen Inc. | V-c-fc-v-c antibody |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| PE20210648A1 (es) | 2013-12-17 | 2021-03-26 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
| CA2932364A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with improved protein a-binding |
| HRP20200164T1 (hr) | 2014-03-28 | 2020-05-01 | Xencor, Inc. | Bispecifična protutijela koja se vežu na cd38 i cd3 |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| US11306156B2 (en) | 2014-05-28 | 2022-04-19 | Zymeworks Inc. | Modified antigen binding polypeptide constructs and uses thereof |
| EP3174903B1 (en) | 2014-07-31 | 2024-04-10 | Amgen Research (Munich) GmbH | Bispecific single chain antibody construct with enhanced tissue distribution |
| ES2743809T3 (es) | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| EA038958B1 (ru) | 2014-08-04 | 2021-11-15 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| US10105142B2 (en) | 2014-09-18 | 2018-10-23 | Ethicon Llc | Surgical stapler with plurality of cutting elements |
| AU2015323313B2 (en) | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| DK3223845T3 (da) | 2014-11-26 | 2021-08-16 | Xencor Inc | Heterodimere antistoffer, der binder cd3 og cd20 |
| PE20171103A1 (es) | 2014-11-26 | 2017-08-07 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CN104829728B (zh) | 2015-01-21 | 2019-03-12 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体her2xcd3的构建及应用 |
| CN104829726B (zh) | 2015-01-21 | 2019-03-05 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd19xcd3的构建及应用 |
| CN114230668B (zh) | 2015-01-23 | 2025-07-11 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
| WO2016123675A1 (en) | 2015-02-05 | 2016-08-11 | The University Of Queensland | Targeting constructs for delivery of payloads |
| MX2017013348A (es) | 2015-04-17 | 2018-08-01 | Amgen Res Munich Gmbh | Construcciones de anticuerpos biespecificos contra cdh3 y cd3. |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| HRP20201375T1 (hr) | 2015-08-17 | 2020-11-27 | Janssen Pharmaceutica Nv | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE |
| EA201891084A1 (ru) | 2015-11-02 | 2019-10-31 | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
| US9552854B1 (en) | 2015-11-10 | 2017-01-24 | Intel Corporation | Register files including distributed capacitor circuit blocks |
| UA126657C2 (uk) | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| UY37105A (es) | 2016-02-03 | 2017-09-29 | Amgen Res (Munich) Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
| SMT202200359T1 (it) | 2016-09-23 | 2022-11-18 | Regeneron Pharma | Anticorpi anti-muc16 (mucina 16) |
| KR102687833B1 (ko) | 2016-11-02 | 2024-07-24 | 브리스톨-마이어스 스큅 컴퍼니 | 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도 |
| US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2016
- 2016-07-29 TW TW105124268A patent/TWI829617B/zh active
- 2016-07-31 JO JOP/2016/0165A patent/JO3792B1/ar active
- 2016-08-01 FI FIEP16756952.4T patent/FI3328891T3/fi active
- 2016-08-01 EP EP23157688.5A patent/EP4219562A3/en active Pending
- 2016-08-01 US US15/225,568 patent/US11447567B2/en active Active
- 2016-08-01 LT LTEPPCT/EP2016/068319T patent/LT3328891T/lt unknown
- 2016-08-01 IL IL289894A patent/IL289894B2/en unknown
- 2016-08-01 KR KR1020187002505A patent/KR20180030852A/ko not_active Ceased
- 2016-08-01 HU HUE16756952A patent/HUE061579T2/hu unknown
- 2016-08-01 MX MX2018001159A patent/MX2018001159A/es unknown
- 2016-08-01 DK DK16756952.4T patent/DK3328891T5/da active
- 2016-08-01 ES ES16756952T patent/ES2943147T3/es active Active
- 2016-08-01 SM SM20230131T patent/SMT202300131T1/it unknown
- 2016-08-01 HR HRP20230401TT patent/HRP20230401T1/hr unknown
- 2016-08-01 AU AU2016302580A patent/AU2016302580B2/en active Active
- 2016-08-01 SG SG10202000793XA patent/SG10202000793XA/en unknown
- 2016-08-01 RS RS20230314A patent/RS64184B1/sr unknown
- 2016-08-01 PT PT167569524T patent/PT3328891T/pt unknown
- 2016-08-01 PE PE2018000149A patent/PE20181082A1/es unknown
- 2016-08-01 TN TNP/2017/000550A patent/TN2017000550A1/en unknown
- 2016-08-01 PL PL16756952.4T patent/PL3328891T3/pl unknown
- 2016-08-01 JP JP2018504926A patent/JP7011574B2/ja active Active
- 2016-08-01 MY MYPI2018700199A patent/MY193235A/en unknown
- 2016-08-01 UA UAA201801769A patent/UA125717C2/uk unknown
- 2016-08-01 EP EP16756952.4A patent/EP3328891B1/en active Active
- 2016-08-01 CR CR20180067A patent/CR20180067A/es unknown
- 2016-08-01 MD MDE20180564T patent/MD3328891T2/ro unknown
- 2016-08-01 SI SI201631690T patent/SI3328891T1/sl unknown
- 2016-08-01 CN CN202211134260.9A patent/CN115925964A/zh active Pending
- 2016-08-01 CN CN201680044598.1A patent/CN109476735B/zh active Active
- 2016-08-01 CA CA2991607A patent/CA2991607A1/en active Pending
- 2016-08-01 EA EA201890337A patent/EA201890337A8/ru unknown
- 2016-08-01 BR BR112018001042A patent/BR112018001042A2/pt not_active Application Discontinuation
- 2016-08-01 WO PCT/EP2016/068319 patent/WO2017021362A1/en active Application Filing
-
2018
- 2018-01-09 IL IL256821A patent/IL256821B/en unknown
- 2018-01-19 PH PH12018500157A patent/PH12018500157A1/en unknown
- 2018-01-29 CO CONC2018/0000882A patent/CO2018000882A2/es unknown
- 2018-01-30 CL CL2018000269A patent/CL2018000269A1/es unknown
-
2021
- 2021-03-23 CL CL2021000716A patent/CL2021000716A1/es unknown
-
2022
- 2022-01-14 JP JP2022004318A patent/JP2022062061A/ja active Pending
- 2022-07-19 US US17/813,434 patent/US20230272113A1/en active Pending
- 2022-09-08 CL CL2022002448A patent/CL2022002448A1/es unknown
-
2023
- 2023-05-18 CY CY20231100234T patent/CY1126145T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230401T1 (hr) | Konstrukti protutijela za flt3 i cd3 | |
| HRP20231410T1 (hr) | Konstrukti bispecifičnih antitijela koji vežu mezotelin i cd3 | |
| HRP20191983T1 (hr) | Konstrukti protutijela za cdh19 i cd3 | |
| HRP20211073T1 (hr) | Konstrukti bispecifičnih protutijela koji vežu dll3 i cd3 | |
| HRP20120759T1 (hr) | Bispecifična veziva specifična između vrsta | |
| IL295534A (en) | Improved immunoglobulin variable domains | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| JP2013063981A5 (hr) | ||
| HRP20130883T4 (hr) | Međuvrsno specifična cd3-epsilon-vežuća domena | |
| JP2016511277A5 (hr) | ||
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| JP2016511750A5 (hr) | ||
| ME02581B (me) | Farmaceutski pripravci s otpornošću na topljivi cea | |
| IL256870B2 (en) | Constructs for bispecific antibodies that bind to CD70 and CD3 and uses thereof | |
| JP2010524435A5 (hr) | ||
| IL245001B2 (en) | Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses | |
| JP2010022372A5 (hr) | ||
| HRP20110187T1 (hr) | Multispecifične deimunizirane tvari koje vežu cd3 | |
| JP2015504306A5 (hr) | ||
| HRP20200306T1 (hr) | Bispecifične molekule vezane na antigene koji aktiviraju t stanice specifične za cd3 i cea | |
| RU2012130840A (ru) | Соединения | |
| JP2017522892A5 (hr) | ||
| RU2009120699A (ru) | Гуманизированные антитела к фактору d и их применения | |
| HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću |